Description

Ragonat 40 mg contains Regorafenib, an oral targeted therapy that inhibits several protein kinases involved in tumor cell proliferation, angiogenesis, and the tumor microenvironment. It is typically prescribed for patients who have progressed after standard treatments.

🔬 Mechanism of Action

Regorafenib blocks multiple kinases including VEGFR, PDGFR, FGFR, KIT, RET, and RAF kinases. As a result, it:

• Inhibits tumor blood vessel formation (anti-angiogenic effect)
• Suppresses tumor cell growth
• Interferes with oncogenic signaling pathways
• This broad-spectrum activity makes it effective in previously treated advanced cancers.

💊 Indications

Ragonat 40 mg is indicated for:

• Metastatic Colorectal Cancer (mCRC) after prior therapies
• Gastrointestinal Stromal Tumor (GIST) after failure of imatinib and sunitinib
• Hepatocellular Carcinoma (HCC) previously treated with sorafenib

📌 Key Features of Ragonat 40 mg

• Strength: 40 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Multi-kinase inhibitor
• Typical Regimen: 160 mg once daily (4 tablets of 40 mg) for 21 days followed by 7 days off (28-day cycle), as prescribed
• Monitoring: Liver function tests and blood pressure monitoring required

⚕️ Benefits of Regorafenib

• Targeted therapy for advanced cancers
• Oral administration for patient convenience
• Helps prolong overall survival in indicated conditions
• Effective after failure of first-line treatments

⚠️ Precautions

• Risk of hepatotoxicity — liver function must be monitored closely
• May cause hypertension, hand-foot skin reaction, diarrhea, and fatigue
• Risk of bleeding and impaired wound healing
• Dose adjustments may be required based on tolerance
• Use strictly under oncologist supervision

Ragonat 40 mg (Regorafenib Tablets) provides a valuable targeted treatment option for advanced, previously treated cancers, helping control disease progression and improve patient outcomes when administered under expert medical care.